What is Faeth Therapeutics, Inc.'s (FTH) StockRank?

MoatMap's StockRank for Faeth Therapeutics, Inc. (FTH) is 32/100, with a Sell signal. This is a composite score combining Quality (26), Value (26), and Momentum (68) factor ranks across MoatMap's 20,000+ stock universe.

Does Faeth Therapeutics, Inc. have an economic moat?

Faeth Therapeutics, Inc. (FTH) has a Quality factor score of 26/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Faeth Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Faeth Therapeutics, Inc. (FTH) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Faeth Therapeutics, Inc. in?

Faeth Therapeutics, Inc. (FTH) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

FTH

Sell

Faeth Therapeutics, Inc. · Healthcare · United States · $897M · Avg Vol: $10M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-195.3%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	0	0	0	0	—	—
EPS	-1.89	-1.18	-1.17	-0.82	—	—
Shares	25.8M	25.8M	25.8M	25.8M	0.0%	25.8M
Debt	8.0M	6.2M	3.8M	1.5M	-42.7%	0.6M
Equity	103.4M	64.9M	38.4M	18.6M	-43.6%	—
Op CF	-39.0M	-32.0M	-24.7M	-20.5M	—	-33.9M
Inv CF	49.9M	38.4M	22.4M	19.8M	—	—
Fin CF	-0.3M	-11.2M	-0.8M	-0.6M	—	—

Loading 1Y...

PRICE (1Y)+20.0%

SMA 50SMA 200

$33.84

RSI (14)

69.0

52W High

$37.90

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-991.0%0.3

ROE

-195.3%4.5

GP/Assets

—N/A

Op. Margin

0.0%40.1

FCF/Assets

-89.4%2.7

Piotroski

322.5

Int. Cover

-50.0x6.2

D/E Ratio

0.00x90.0

Current Ratio

19.69x95.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-18.2x25.0

P/FCF

—N/A

P/B

4.9x29.3

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

89%81.7

RS 6M

-2%61.9

SMA 50/200

1.35x95.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+92%72.3

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$897M

P/E (Forward)

-6.6x

Gross Margin

—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FTH are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
FTH	Faeth Therapeutics, Inc.(you)	$897M	32	Sell
CADL	Candel Therapeutics, Inc.	$984M	31	Sell
DSGN	Design Therapeutics, Inc.	$953M	34	Sell
IMMX	Immix Biopharma, Inc.	$969M	34	Sell
NGNE	Neurogene Inc.	$793M	34	Sell
LXRX	Lexicon Pharmaceuticals, Inc.	$1.0B	34	Sell
AVTX	Avalo Therapeutics, Inc.	$1.0B	29	Sell
FDMT	4D Molecular Therapeutics, Inc.	$850M	26	Sell
APMD	Apnimed, Inc.	$1.0B	36	Hold
JANX	Janux Therapeutics, Inc.	$1.1B	29	Sell

Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%

Faeth Therapeutics, Inc. (FTH): Stock Score Summary

Faeth Therapeutics, Inc. (FTH) has a MoatMap StockRank of 32/100 based on Quality (26/100), Value (26/100), and Momentum (68/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$33.84
Market Cap	$897M
P/E (Forward)	-6.65
Price/Book	4.92
Return on Equity	-195.3%
Return on Invested Capital	-991.0%
Debt/Equity	0.00x
Operating Margin	0.0%
Free Cash Flow	$-20M

Faeth Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Faeth Therapeutics, Inc.’s (FTH) StockRank?: MoatMap’s StockRank for Faeth Therapeutics, Inc. (FTH) is 32/100, with a Sell signal. It is a composite of Quality (26), Value (26), and Momentum (68) factor ranks across MoatMap’s 20,000+ stock universe.
Does Faeth Therapeutics, Inc. have an economic moat?: Faeth Therapeutics, Inc. (FTH) has a Quality factor score of 26/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Faeth Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Faeth Therapeutics, Inc. (FTH) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Faeth Therapeutics, Inc. in?: Faeth Therapeutics, Inc. (FTH) operates in the Healthcare sector, specifically the Biotechnology industry (United States).